The Avian Influenza drugs in development market research report provides comprehensive information on the therapeutics under development for Avian Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Avian Influenza. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Avian Influenza - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Avian Influenza and features dormant and discontinued products.

GlobalData tracks 60 drugs in development for Avian Influenza by 52 companies/universities/institutes. The top development phase for Avian Influenza is preclinical with 32 drugs in that stage. The Avian Influenza pipeline has 42 drugs in development by companies and 18 by universities/ institutes. Some of the companies in the Avian Influenza pipeline products market are: National Institute of Allergy and Infectious Diseases, Butantan Institute and Aphios.

The key targets in the Avian Influenza pipeline products market include Hemagglutinin, Hemagglutinin HA (HA), and Hemagglutinin (H7HA).

The key mechanisms of action in the Avian Influenza pipeline product include RNA Polymerase (EC Inhibitor with two drugs in Phase III. The Avian Influenza pipeline products include seven routes of administration with the top ROA being Intramuscular and 13 key molecule types in the Avian Influenza pipeline products market including Small Molecule, and Subunit Vaccine.

Avian Influenza overview

Avian influenza, commonly referred to as bird flu, is a viral infection that primarily affects birds, especially poultry such as chickens and turkeys. Various strains of avian influenza viruses exist, some of which can cause severe illness in birds and, in certain cases, pose a risk to human health. Avian influenza viruses belong to the influenza A virus family and are classified based on surface proteins: hemagglutinin (H) and neuraminidase (N). The H5, H7, and H9 subtypes are of particular concern due to their potential to cause severe disease in birds and occasionally transmit to humans. Avian influenza viruses primarily circulate among birds and can spread through direct contact with infected birds, their feces, respiratory secretions, or contaminated surfaces. Human infections often occur through close contact with infected birds or environments contaminated with the virus. While most avian influenza viruses do not infect humans, certain strains, particularly H5N1, H7N9, and others, have caused sporadic cases of severe illness and even death in humans. Human infections are rare but can occur following direct contact with infected birds, particularly in settings such as live bird markets or farms.

For a complete picture of Avian Influenza’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.